Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8022MR)

This product GTTS-WQ8022MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8022MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12763MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ2878MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ13424MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ7695MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ14759MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ10729MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ3040MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14108MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW